

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Application Number	09/704,054
	Filing Date	November 1, 2000
	First Named Inventor	Robert D'Amato
	Art Unit	1614
	Examiner Name	Anderson, James D.
	Attorney Docket No.	9516-039-999

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C347	Alexanian, Raymond <i>et al.</i> , "Thalidomide for Resistant and Relapsing Myeloma," <i>Seminars in Hematology</i> , 2000, 37(1)Supp 3:22-25	
	C348	Bertolini, F. <i>et al.</i> , "Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers," <i>Annals of Oncology</i> , 2001, 12:987-990	
	C349	Cavenaugh, Jamie D., "Thalidomide in Multiple Myeloma: Current Status and Future Prospects," <i>British Journal of Haematology</i> , 2003, 120:18-26	
	C350	D'Amato, Robert <i>et al.</i> , "Mechanism of Action of Thalidomide and 3-Aminothalidomide in Multiple Myeloma," <i>Seminars in Oncology</i> , 2001, 28(6): 597-601	
	C351	Juliussen, Gunnar <i>et al.</i> , "Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma," <i>British Journal of Haematology</i> , 2000, 109:89-96	
	C352	Kakimoto, T. <i>et al.</i> , "Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome," <i>Jpn. J. Cancer Res.</i> , 2002, 93:1029-1036	
	C353	Kneller, A. <i>et al.</i> , "Therapy with thalidomide in refractory multiple myeloma patients – the revival of an old drug," <i>British Journal of Haematology</i> , 2000, 108:391-393	
	C354	Kumar, S. <i>et al.</i> , "Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma," <i>Leukemia</i> , 2004, 1-4	
	C355	Kumar, S. <i>et al.</i> , "Thalidomide as an anti-cancer agent," <i>J. Cell. Mol. Med.</i> , 2002, 6(2):160-174	
	C356	Peuckmann, Vera <i>et al.</i> , "Potential Novel Uses of Thalidomide," <i>Drugs</i> , 2000, 60(2):273-292	
	C357	Raje, Noopur <i>et al.</i> , "Thalidomide and immunology drugs as cancer therapy," <i>Current Opinions in Oncology</i> , 2002, 14:635-640	
	C358	Rajkumar, S.V. <i>et al.</i> , "Thalidomide for previously untreated indolent or smoldering multiple myeloma," <i>Leukemia</i> , 2001, 15:1274-1276	
	C359	Rajkumar, S.V. <i>et al.</i> , "Thalidomide in the Treatment of Relapsed Multiple Myeloma," <i>Mayo Clin Proc.</i> , 2000, 75:897-901	

NYI-4161898v1

EXAMINER SIGNATURE	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	09/704,054
Filing Date	November 1, 2000
First Named Inventor	Robert D'Amato
Art Unit	1614
Examiner Name	Anderson, James D.
Attorney Docket No.	9516-039-999

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C360	Rajkumar, S.V., "Thalidomide in the treatment of multiple myeloma," <i>Expert Rev. Anticancer Ther.</i> , 2001, 1(1):20-28	
	C361	Ribatti, D. <i>et al.</i> , "Is thalidomide a true anti-angiogenic molecule in multiple myeloma?" <i>Haematologica</i> , 2002, 87(4):344-345	
	C362	Richardson, Paul <i>et al.</i> , "Thalidomide: Emerging Role in Cancer Medicine," <i>Annu. Rev. Med.</i> , 2002, 53:629-657	
	C363	Roe, F.J.C., "Research on Anticarcinogenic Effects of Thalidomide," <i>The Practitioner</i> , 1974, 212(1269):296-297	
	C364	Tosi, Patrizia <i>et al.</i> , "Thalidomide in multiple myeloma: state of art" <i>Haematologica</i> , 2002, 87(3):233-234	
	C365	Vacca, A. <i>et al.</i> , "Bone marrow angiogenesis and progression in multiple myeloma," <i>British Journal of Haematology</i> , 1994, 87:503-508	

NYI-4161898v1

**EXAMINER
SIGNATURE**

/James Anderson/

DATE CONSIDERED

03/12/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/